Cortexyme Stock News

Insider and Institutional Ownership 63.2% of Cortexyme shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 27.9% of Cort

Profitability This table compares SQZ Biotechnologies and Cortexyme's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -11

Institutional and Insider Ownership 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 27.9% of C

Valuation and Earnings This table compares Eloxx Pharmaceuticals and Cortexyme"s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share

Insider and Institutional Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Elo

Institutional and Insider Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Elo

Prime Medicine (NYSE: PRME - Get Free Report) and Cortexyme (NASDAQ: CRTX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two busine

Cortexyme, Inc. (NASDAQ: CRTX - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.54 and traded as high as $1.95

Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Intere

Cortexyme (CRTX) said its drug COR588 was well-tolerated and safe in a single ascending dose ((SAD)) portion of a phase 1 trial.The company is developing COR588 to treat diseases…

Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.

COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.

NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.

An investigation for investors in Cortexyme, Inc. (NASDAQ:CRTX) shares over potential securities laws violations by Cortexyme, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 02/24/2022 -- Cortexyme, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Cortexyme, Inc. (NASDAQ: CRTX), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Cortexyme, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. San Francisco, CA based Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer''s disease and other degenerative disorders. On October 26, 2021, Cortexyme, Inc. issued a press release "report[ing] top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis)." The press release reported, in relevant part, that the study had failed to meet statistical significance in its co-primary endpoints of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer''s disease.